This article was originally published in SRA
US FDA changes e-portal for public comments
You may also be interested in...
Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.
FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.